# Vertex Pharmaceuticals (VRTX) SEC filings

URL: https://funkfolio.com/stock/VRTX/filings

> Vertex Pharmaceuticals (VRTX) SEC filings from EDGAR: 10-K filed Feb 13, 2026, 10-Q filed Nov 3, 2026, 8-K filed Nov 2, 2026.

---

## Vertex Pharmaceuticals (VRTX) SEC filings

Vertex Pharmaceuticals's latest annual report is a Form 10-K filed on February 13, 2026 for the period ended December 31, 2025. Its latest quarterly report, a Form 10-Q, was filed on November 3, 2026. Its latest current report, a Form 8-K, was filed on November 2, 2026 (2.02 Results of Operations and Financial Condition).

### Key facts

- **Latest annual report:** 10-K, Feb 13, 2026
- **Latest quarterly report:** 10-Q, Nov 3, 2026
- **Latest 8-K:** 8-K, Nov 2, 2026
- **Filings, last 12 months:** 208
- **Insider forms, last 12 months:** 115 Forms 3, 4 and 5
- **13D and 13G, last 12 months:** 6
- **SEC central index key:** 0000875320

Filings as listed by SEC EDGAR at Nov 18, 2026, 05:15 UTC (re-read at most hourly). Source: [SEC EDGAR filings for CIK 0000875320](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320). Every form links to its document on sec.gov. Older filings are in EDGAR's archive; the tables here cover its recent list (at least the last year).

### Annual and quarterly reports

Vertex Pharmaceuticals: annual and quarterly reports filed with the SEC

| Form | Filed | Period ended | Document |
| --- | --- | --- | --- |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm) | Nov 3, 2026 | Sep 30, 2026 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) | Aug 4, 2026 | Jun 30, 2026 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) | May 5, 2026 | Mar 31, 2026 | Quarterly report |
| [10-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm) | Feb 13, 2026 | Dec 31, 2025 | Annual report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/vrtx-20250930.htm) | Nov 4, 2025 | Sep 30, 2025 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm) | Aug 5, 2025 | Jun 30, 2025 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm) | May 6, 2025 | Mar 31, 2025 | Quarterly report |
| [10-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm) | Feb 13, 2025 | Dec 31, 2024 | Annual report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/vrtx-20240930.htm) | Nov 5, 2024 | Sep 30, 2024 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/vrtx-20240630.htm) | Aug 2, 2024 | Jun 30, 2024 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/vrtx-20240331.htm) | May 7, 2024 | Mar 31, 2024 | Quarterly report |
| [10-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/vrtx-20231231.htm) | Feb 15, 2024 | Dec 31, 2023 | Annual report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/vrtx-20230930.htm) | Nov 7, 2023 | Sep 30, 2023 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/vrtx-20230630.htm) | Aug 2, 2023 | Jun 30, 2023 | Quarterly report |
| [10-Q](https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/vrtx-20230331.htm) | May 2, 2023 | Mar 31, 2023 | Quarterly report |
| [10-K](https://www.sec.gov/Archives/edgar/data/875320/000087532023000007/vrtx-20221231.htm) | Feb 10, 2023 | Dec 31, 2022 | Annual report |

The latest 16 of 26 in EDGAR's recent list. Amended reports are marked. The period is the fiscal year or quarter the report covers.

### Current reports (8-K)

Vertex Pharmaceuticals: current reports on Form 8-K and the items each reports

| Form | Filed | Event date | What it reports |
| --- | --- | --- | --- |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/vrtx-20261102.htm) | Nov 2, 2026 | Nov 2, 2026 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm) | Oct 20, 2026 | Oct 20, 2026 | 5.02 Departure or Election of Directors or Officers; Officer Compensation |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm) | Sep 1, 2026 | Aug 27, 2026 | 5.02 Departure or Election of Directors or Officers; Officer Compensation |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm) | Aug 3, 2026 | Aug 3, 2026 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/d113650d8k.htm) | Jul 7, 2026 | Jul 6, 2026 | 1.01 Entry into a Material Definitive Agreement 7.01 Regulation FD Disclosure 8.01 Other Events 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/vrtx-20260513.htm) | May 13, 2026 | May 13, 2026 | 5.02 Departure or Election of Directors or Officers; Officer Compensation 5.07 Submission of Matters to a Vote of Security Holders |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/vrtx-20260504.htm) | May 4, 2026 | May 4, 2026 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000166/vrtx-20260428.htm) | Apr 29, 2026 | Apr 28, 2026 | 5.02 Departure or Election of Directors or Officers; Officer Compensation |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/vrtx-20260331.htm) | Mar 31, 2026 | Mar 31, 2026 | 8.01 Other Events |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/vrtx-20260212.htm) | Feb 12, 2026 | Feb 12, 2026 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/vrtx-20251103.htm) | Nov 3, 2025 | Nov 3, 2025 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/vrtx-20250804.htm) | Aug 4, 2025 | Aug 4, 2025 | 2.02 Results of Operations and Financial Condition 5.02 Departure or Election of Directors or Officers; Officer Compensation 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000199/vrtx-20250519.htm) | May 19, 2025 | May 19, 2025 | 8.01 Other Events |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000194/vrtx-20250514.htm) | May 14, 2025 | May 14, 2025 | 5.07 Submission of Matters to a Vote of Security Holders |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/vrtx-20250505.htm) | May 5, 2025 | May 5, 2025 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000156/vrtx-20250328.htm) | Mar 28, 2025 | Mar 28, 2025 | 8.01 Other Events |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/vrtx-20250204.htm) | Feb 10, 2025 | Feb 4, 2025 | 2.02 Results of Operations and Financial Condition 5.02 Departure or Election of Directors or Officers; Officer Compensation 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm) | Dec 20, 2024 | Dec 20, 2024 | 7.01 Regulation FD Disclosure |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/vrtx-20241104.htm) | Nov 4, 2024 | Nov 4, 2024 | 2.02 Results of Operations and Financial Condition 9.01 Financial Statements and Exhibits |
| [8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000207/vrtx-20240815.htm) | Aug 16, 2024 | Aug 15, 2024 | 1.01 Entry into a Material Definitive Agreement |

The latest 20 of 55 in EDGAR's recent list. Item names are the SEC's own, from Form 8-K (a few long ones shortened). The event date is the date of the earliest event reported.

### Insider forms (3, 4 and 5)

Vertex Pharmaceuticals: insider forms 3, 4 and 5 filed per month over the last twelve months

| Month | Forms filed |
| --- | --- |
| Nov 2026 | 2 |
| Oct 2026 | 4 |
| Sep 2026 | 3 |
| Aug 2026 | 1 |
| Jul 2026 | 7 |
| Jun 2026 | 6 |
| May 2026 | 13 |
| Apr 2026 | 4 |
| Mar 2026 | 9 |
| Feb 2026 | 45 |
| Jan 2026 | 15 |
| Dec 2025 | 4 |

Vertex Pharmaceuticals: the latest insider forms

| Form | Filed | Transaction date |
| --- | --- | --- |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000295/xslF345X06/wk-form4_1794864658.xml) | Nov 16, 2026 | Nov 12, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000293/xslF345X06/wk-form4_1794345641.xml) | Nov 10, 2026 | Nov 6, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000283/xslF345X06/wk-form4_1792699856.xml) | Oct 22, 2026 | Oct 20, 2026 |
| [3](https://www.sec.gov/Archives/edgar/data/875320/000087532026000281/xslF345X06/wk-form3_1792699559.xml) | Oct 22, 2026 | Oct 20, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000276/xslF345X06/wk-form4_1792441385.xml) | Oct 19, 2026 | Oct 15, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000274/xslF345X06/wk-form4_1792441279.xml) | Oct 19, 2026 | Oct 15, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000272/xslF345X06/wk-form4_1789072310.xml) | Sep 10, 2026 | Sep 8, 2026 |
| [3](https://www.sec.gov/Archives/edgar/data/875320/000087532026000270/xslF345X06/wk-form3_1789071367.xml) | Sep 10, 2026 | Sep 8, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000267/xslF345X06/wk-form4_1788295172.xml) | Sep 1, 2026 | Aug 28, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000261/xslF345X06/wk-form4_1788207608.xml) | Aug 31, 2026 | Aug 27, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000253/xslF345X06/wk-form4_1784837739.xml) | Jul 23, 2026 | Jul 21, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000251/xslF345X06/wk-form4_1784837586.xml) | Jul 23, 2026 | Jul 21, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000249/xslF345X06/wk-form4_1784318797.xml) | Jul 17, 2026 | Jul 15, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000247/xslF345X06/wk-form4_1784318742.xml) | Jul 17, 2026 | Jul 15, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000245/xslF345X06/wk-form4_1783455338.xml) | Jul 7, 2026 | Jul 2, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000243/xslF345X06/wk-form4_1783454880.xml) | Jul 7, 2026 | Jul 2, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000241/xslF345X06/wk-form4_1783368787.xml) | Jul 6, 2026 | Jul 1, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000239/xslF345X06/wk-form4_1782850180.xml) | Jun 30, 2026 | Jun 26, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000237/xslF345X06/wk-form4_1782245334.xml) | Jun 23, 2026 | Jun 18, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/xslF345X06/wk-form4_1781727153.xml) | Jun 17, 2026 | Jun 15, 2026 |

The latest 20 of 661 in EDGAR's recent list. Each form is filed by the insider about their own holding; the trade details are inside the form on sec.gov. Counts include amendments. The current month is counted to date.

### Ownership reports (Schedules 13D and 13G)

Vertex Pharmaceuticals: Schedule 13D and 13G beneficial ownership reports

| Form | Filed | Event date |
| --- | --- | --- |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284826000142/xslSCHEDULE_13G_X02/primary_doc.xml) | Nov 13, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284926000080/xslSCHEDULE_13G_X02/primary_doc.xml) | May 14, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284826000067/xslSCHEDULE_13G_X02/primary_doc.xml) | May 14, 2026 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000210011926001217/xslSCHEDULE_13G_X02/primary_doc.xml) | Apr 30, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000010290926002578/xslSCHEDULE_13G_X02/primary_doc.xml) | Mar 27, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284826000023/xslSCHEDULE_13G_X01/primary_doc.xml) | Feb 12, 2026 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000142284825000080/xslSCHEDULE_13G_X01/primary_doc.xml) | May 13, 2025 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284925000012/xslSCHEDULE_13G_X01/primary_doc.xml) | Feb 13, 2025 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000031506625000927/xslSCHEDULE_13G_X01/primary_doc.xml) | Feb 12, 2025 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284924000023/SEC13G_Filing.htm) | Apr 10, 2024 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000110465924022233/tv02209-vertexpharmaceutical.htm) | Feb 13, 2024 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000142284824000255/SEC13G_Filing.htm) | Feb 9, 2024 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000031506624001554/filing.txt) | Feb 9, 2024 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000108636424003204/us92532f1003_012524.txt) | Jan 25, 2024 | — |
| [Schedule 13D (amended)](https://www.sec.gov/Archives/edgar/data/875320/000134100423000148/sc13d-a1.htm) | Jun 5, 2023 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000142284923000088/SEC13G_Filing.htm) | Feb 13, 2023 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000031506623002082/filing.txt) | Feb 9, 2023 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000110465923017239/tv02181-vertexpharmaceutical.htm) | Feb 9, 2023 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/875320/000130655023002906/us92532f1003_012423.txt) | Jan 24, 2023 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/875320/000008025522001976/vrtx13gadec21.txt) | Feb 14, 2022 | — |

The latest 20 of 28 in EDGAR's recent list. Filed by the holder, not the company. EDGAR's list names the form and date; who filed it is in the document.

### Proxy statements

Vertex Pharmaceuticals: proxy statements and proxy materials

| Form | Filed | Meeting or period | Document |
| --- | --- | --- | --- |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000087532026000167/a2026vertexapril.htm) | Apr 29, 2026 | — |  |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000087532026000154/a2026vertexna.htm) | Apr 2, 2026 | — |  |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000087532026000153/vrtx-20260402.htm) | Apr 2, 2026 | May 13, 2026 | Definitive proxy statement |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000087532025000161/a2025vertexna.htm) | Apr 3, 2025 | — |  |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000087532025000160/vrtx-20250403.htm) | Apr 3, 2025 | May 14, 2025 | Definitive proxy statement |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000130817924000453/lvrtx2024_defa14a.htm) | Apr 4, 2024 | — | VERTEX PHARMACEUTICALS INC - DEFA14A |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000130817924000452/lvrtx2024_def14a.htm) | Apr 4, 2024 | May 15, 2023 | VERTEX PHARMACEUTICALS INC - DEF 14A |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000130817923000592/lvrtx2023_defa14a.htm) | Apr 6, 2023 | — | VERTEX PHARMACEUTICALS INC - DEFA14A |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000130817923000591/lvrtx2023_def14a.htm) | Apr 6, 2023 | — | VERTEX PHARMACEUTICALS INC - DEF 14A |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000130817922000211/lvrtx2022_defa14a.htm) | Apr 7, 2022 | — | VERTEX PHARMACEUTICALS INC - DEFA14A |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000130817922000210/lvrtx2022_def14a.htm) | Apr 7, 2022 | May 18, 2022 | VERTEX PHARMACEUTICALS INC - DEF 14A |
| [DEFA14A](https://www.sec.gov/Archives/edgar/data/875320/000130817921000197/lvrtx_defa14a.htm) | Apr 8, 2021 | — | VERTEX PHARMACEUTICALS INC - DEFA14A |
| [DEF 14A](https://www.sec.gov/Archives/edgar/data/875320/000130817921000196/lvrtx2021_def14a.htm) | Apr 8, 2021 | May 19, 2021 | VERTEX PHARMACEUTICALS INC - DEF 14A |

**Everything else (225 filings: registrations, prospectuses, Rule 144 notices, correspondence and more)**

Vertex Pharmaceuticals: other SEC filings

| Form | Filed | Period | Document |
| --- | --- | --- | --- |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326008021/xsl144X01/primary_doc.xml) | Nov 16, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326008016/xsl144X01/primary_doc.xml) | Nov 16, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326007958/xsl144X01/primary_doc.xml) | Nov 12, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326007810/xsl144X01/primary_doc.xml) | Nov 6, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195824426000559/xsl144X01/primary_doc.xml) | Aug 27, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326005073/xsl144X01/primary_doc.xml) | Jul 2, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326005057/xsl144X01/primary_doc.xml) | Jul 2, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326005009/xsl144X01/primary_doc.xml) | Jul 1, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004906/xsl144X01/primary_doc.xml) | Jun 26, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004764/xsl144X01/primary_doc.xml) | Jun 18, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004654/xsl144X01/primary_doc.xml) | Jun 15, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004391/xsl144X01/primary_doc.xml) | Jun 5, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004191/xsl144X01/primary_doc.xml) | Jun 1, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326004132/xsl144X01/primary_doc.xml) | May 29, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003639/xsl144X01/primary_doc.xml) | May 15, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003628/xsl144X01/primary_doc.xml) | May 15, 2026 | — | Notice of proposed sale |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000220/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000219/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000218/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000217/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000216/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000215/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8 POS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000214/s-8pos2013plan.htm) | May 13, 2026 | — |  |
| [S-8](https://www.sec.gov/Archives/edgar/data/875320/000087532026000206/s-82026plan.htm) | May 13, 2026 | — | Registration statement for employee plans |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003520/xsl144X01/primary_doc.xml) | May 12, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003331/xsl144X01/primary_doc.xml) | May 6, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003218/xsl144X01/primary_doc.xml) | May 4, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326003191/xsl144X01/primary_doc.xml) | May 1, 2026 | — | Notice of proposed sale |
| [UPLOAD](https://www.sec.gov/Archives/edgar/data/875320/000000000026003732/filename1.pdf) | Apr 14, 2026 | — |  |
| [ARS](https://www.sec.gov/Archives/edgar/data/875320/000087532026000155/vrtx_arsxx2025.pdf) | Apr 2, 2026 | Dec 31, 2025 |  |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326002699/xsl144X01/primary_doc.xml) | Apr 1, 2026 | — | Notice of proposed sale |
| [CORRESP](https://www.sec.gov/Archives/edgar/data/875320/000119312526136216/filename1.htm) | Apr 1, 2026 | — |  |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326002646/xsl144X01/primary_doc.xml) | Mar 27, 2026 | — | Notice of proposed sale |
| [UPLOAD](https://www.sec.gov/Archives/edgar/data/875320/000000000026002758/filename1.pdf) | Mar 18, 2026 | — |  |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326002279/xsl144X01/primary_doc.xml) | Mar 13, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326002175/xsl144X01/primary_doc.xml) | Mar 11, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001862/xsl144X01/primary_doc.xml) | Mar 4, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001733/xsl144X01/primary_doc.xml) | Mar 2, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001605/xsl144X01/primary_doc.xml) | Feb 27, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001563/xsl144X01/primary_doc.xml) | Feb 27, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001477/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001473/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001472/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001467/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001460/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001455/xsl144X01/primary_doc.xml) | Feb 25, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001243/xsl144X01/primary_doc.xml) | Feb 19, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001111/xsl144X01/primary_doc.xml) | Feb 18, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001097/xsl144X01/primary_doc.xml) | Feb 18, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001094/xsl144X01/primary_doc.xml) | Feb 18, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001089/xsl144X01/primary_doc.xml) | Feb 18, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001066/xsl144X01/primary_doc.xml) | Feb 17, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001046/xsl144X01/primary_doc.xml) | Feb 17, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001037/xsl144X01/primary_doc.xml) | Feb 17, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326001034/xsl144X01/primary_doc.xml) | Feb 17, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326000977/xsl144X01/primary_doc.xml) | Feb 13, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326000976/xsl144X01/primary_doc.xml) | Feb 13, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326000975/xsl144X01/primary_doc.xml) | Feb 13, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326000856/xsl144X01/primary_doc.xml) | Feb 11, 2026 | — | Notice of proposed sale |
| [144](https://www.sec.gov/Archives/edgar/data/875320/000195917326000853/xsl144X01/primary_doc.xml) | Feb 11, 2026 | — | Notice of proposed sale |

The latest 60 of 225 in EDGAR's recent list.

### What the forms are

**Form 3 — Initial statement of beneficial ownership**

An insider's first statement of holdings in the company's equity securities. Insiders are officers, directors and holders of more than 10 percent of a class of its registered equity securities.

**Form 4 — Statement of changes in beneficial ownership**

An insider's transactions in the company's equity securities, disclosed within two business days of the transaction.

**Form 144 — Notice of proposed sale**

In the SEC's Forms Index: notice of proposed sale of securities pursuant to Rule 144.

**Form 10-K — Annual report**

Audited annual financial statements, a discussion of material risk factors, and management's discussion and analysis of the results for the prior fiscal year.

**Form 10-Q — Quarterly report**

Unaudited quarterly financial statements, updates on material risks, and management's discussion and analysis of the results for the prior fiscal quarter.

**Form 8-K — Current report**

Discloses material events or information the company chooses or is required to make public before its next scheduled quarterly or annual report. Each report lists the items it covers.

**Schedule 13D — Schedule 13D beneficial ownership report**

Filed when a party acquires more than five percent of a class of the company's registered voting securities; also used to disclose later changes to the holding.

**Schedule 13G — Schedule 13G beneficial ownership report**

Filed when a party acquires more than five percent of a class of the company's registered voting securities as a passive investment.

**Form DEF 14A — Definitive proxy statement**

The final proxy statement sent to shareholders for a shareholder meeting: the matters to be voted on, and typically executive and board compensation and who owns more than five percent.

**Form S-8 — Registration statement for employee plans**

In the SEC's Forms Index: registration statement under the Securities Act of 1933 for securities to be offered to employees under certain plans.

**Form S-3 — Short-form registration statement**

An abbreviated registration statement available to certain already-reporting companies to register the offer and sale of securities to the public.

From the SEC's own descriptions: [SEC, Using EDGAR to Research Investments](https://www.sec.gov/search-filings/edgar-search-assistance/using-edgar-research-investments); [SEC, Forms Index](https://www.sec.gov/submit-filings/forms-index); [SEC, Form 8-K and its items (PDF)](https://www.sec.gov/files/form8-k.pdf).

### Questions and answers

**Where is Vertex Pharmaceuticals's latest annual report (10-K)?**

Vertex Pharmaceuticals filed its latest Form 10-K with the SEC on February 13, 2026 for the period ended December 31, 2025. The table of annual and quarterly reports on this page links to the document on sec.gov.

**When did Vertex Pharmaceuticals file its latest 10-Q?**

On November 3, 2026 for the period ended September 30, 2026. A Form 10-Q holds unaudited quarterly financial statements and management's discussion of the quarter.

**What has Vertex Pharmaceuticals reported on Form 8-K recently?**

Its latest 8-K was filed on November 2, 2026 (2.02 Results of Operations and Financial Condition). In the last twelve months the items it reported most often were: 2.02 Results of Operations and Financial Condition (4 reports); 5.02 Departure or Election of Directors or Officers; Officer Compensation (4 reports); 8.01 Other Events (2 reports). An 8-K discloses material events before the next quarterly or annual report.

**How many insider filings (Forms 3, 4 and 5) were there for VRTX in the last year?**

115 insider forms in the twelve months to November 18, 2026, the latest a Form 4 filed on November 16, 2026. Officers, directors and holders of more than 10 percent of a class of the company's registered equity securities must disclose their holdings and transactions; a Form 4 is due within two business days of a trade.

**Has anyone reported owning more than 5% of Vertex Pharmaceuticals?**

EDGAR lists 6 Schedule 13D or 13G filings about Vertex Pharmaceuticals in the last twelve months, the latest on November 13, 2026. These are filed by a party that acquires more than five percent of a class of the company's voting securities; 13G is for passive investors.

### Learn

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) SEC filings”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/filings

Underlying data: SEC EDGAR submissions (data.sec.gov).
